Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Adagio Therapeutics
303 Wyman Street Suite 300
Waltham, MA 02451
Phone: 781-248-2771
www.adagiotx.com

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic in early 2021.

Key Contact
Name
Tillman Gerngross, Ph.D.
Title
CEO
Funding Events

Date
Amount
Type
Investors
11/10/20 $80,000,000 Series B Fidelity Management & Research Company
GV
Mithril Capital Management
Omega Funds
OrbiMed Advisors
Polaris Partners
Population Health Partners
04/20/21 $336,000,000 Series C ArrowMark Partners
Federated Hermes
Fidelity Management & Research Company
Foresite Capital
GV
Mithril Capital Management
OrbiMed Advisors
Polaris Partners
Population Health Partners
PremjiInvest
RA Capital Management
Redmile Group


Featured Reading